Good growth in Q2, driven mainly by strong sales in Sweden

Q2 · Net sales reached SEK 6.4 (5.3) million.  · Result after tax came in at SEK -15.7 (-15.5) million.  · Earnings per share, basic and diluted, were SEK -0.11 (-0.17).  · Cash and cash equivalents were SEK 40.8 (3.2) million Significant events in Q2 · Enzymatica signed agreement with German Maren for delivery of enzyme formulation for skin care products. The agreement is worth SEK 120 million over three years. · Enzymatica completed recruitment of patients to a double-blind, placebo-controlled multicenter study in Germany to evaluate the effects of ColdZyme on